Precipio マネジメント

マネジメント基準チェック /44

Precipioの CEO はIlan Danieliで、 Jun2017年に任命され、の在任期間は 7.42年です。の年間総報酬は$ 473.44Kで、 63.4%給与と36.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.19%を直接所有しており、その価値は$ 16.86K 。経営陣と取締役会の平均在任期間はそれぞれ7.4年と4.9年です。

主要情報

Ilan Danieli

最高経営責任者

US$473.4k

報酬総額

CEO給与比率	63.4%
CEO在任期間	7.4yrs
CEOの所有権	0.2%
経営陣の平均在職期間	7.4yrs
取締役会の平均在任期間	4.9yrs

経営陣の近況

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Jun 07

Recent updates

Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price Boost

Aug 21

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Jun 07

We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation

Jun 12

Precipio shares surge on HemeScreen Anemia Panel launch

Jun 08

Precipio shares surge on launching hemescreen panel for Acute Myeloid Leukemia

May 10

Precipio: COVID-19 Testing At Amazon Is An Impressive Yet Transitory Fluke

May 05

Precipio shares jump on launching its rapid COVID-19 antibody test on Amazon platform

May 03

CEO報酬分析

Precipio の収益と比較して、Ilan Danieli の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$3m
Jun 30 2024	n/a	n/a	-US$4m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$473k	US$300k	-US$6m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$11m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$805k	US$300k	-US$12m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$2m	US$300k	-US$9m
Sep 30 2021	n/a	n/a	-US$8m
Jun 30 2021	n/a	n/a	-US$10m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	US$452k	US$261k	-US$14m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$298k	US$250k	-US$13m
Sep 30 2019	n/a	n/a	-US$16m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$914k	US$250k	-US$20m
Sep 30 2018	n/a	n/a	-US$26m
Jun 30 2018	n/a	n/a	-US$33m
Mar 31 2018	n/a	n/a	-US$38m
Dec 31 2017	US$369k	US$250k	-US$33m

報酬と市場: Ilanの総報酬 ($USD 473.44K ) は、 US市場 ($USD 650.80K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Ilanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Ilan Danieli (52 yo)

7.4yrs

在職期間

US$473,440

報酬

Mr. Ilan Danieli is the Founder of Precipio, Inc. and has been its Chief Executive Officer since June 29, 2017 and serves as its President and Director. Mr. Danieli has few years managing small and medium-...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ilan Danieli	Founder	7.4yrs	US$473.44k	0.19% $ 16.9k
Ahmed Sabet	Chief Operating Officer	7.4yrs	US$265.34k	0.041% $ 3.6k
Ayman Mohamed	Chief Technology Officer	no data	US$284.50k	0.013% $ 1.1k
Matthew Gage	Chief Financial Officer	2.7yrs	データなし	データなし
Miri Chiko-Radomski	Chief Legal Counsel & People Officer	no data	データなし	データなし

7.4yrs

平均在職期間

45.5yo

平均年齢

経験豊富な経営陣: PRPOの経営陣は経験豊富で経験豊富です（平均在職期間は7.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Ilan Danieli	Founder	7.4yrs	US$473.44k	0.19% $ 16.9k
Kathleen LaPorte	Independent Non Executive Director	6.3yrs	US$72.81k	0.68% $ 59.5k
Richard Sandberg	Independent Chairman of the Board	4.9yrs	US$98.43k	0.0028% $ 247.9
Ronald Andrews	Independent Director	3.7yrs	US$60.81k	0.75% $ 65.8k
Christina Valauri	Director	less than a year	データなし	0.34% $ 29.7k
Douglas Fisher	Board Observer	less than a year	US$74.24k	0% $ 0
David Cohen	Independent Director	7yrs	US$59.73k	3.21% $ 281.1k
Jeffrey Cossman	Independent Director	7.2yrs	US$64.01k	0.83% $ 72.8k
Mark Rimer	Board Observer	3.7yrs	US$159.25k	データなし
Mike Makrigiorgos	Member of Scientific Advisory Board	no data	データなし	データなし
Gil Mor	Member of Scientific Advisory Board	no data	データなし	データなし

4.9yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: PRPOの取締役会は経験豊富であると考えられます ( 4.9年の平均在任期間)。

Precipio マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Precipio, Inc., Annual General Meeting, Jun 13, 2024

Precipio, Inc. Announces Board Changes

Precipio, Inc. Appoints Sharon Robins as its Senior Director of Laboratory & Hospital Sales for the Product’s Division

Precipio, Inc. Welcomes Toni-Ann Mills as its Senior Director for Learning & Development

Precipio, Inc. Appoints Keith Meadors as Senior Vice President of its Products Division

Recent updates

Third quarter 2024 earnings released: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023)

Precipio Expands Bloodhound MPN Panel by Adding CALR Mutation Subtyping

Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price Boost

Second quarter 2024 earnings released: US$0.83 loss per share (vs US$1.88 loss in 2Q 2023)

New minor risk - Share price stability

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

First quarter 2024 earnings released: US$1.46 loss per share (vs US$2.61 loss in 1Q 2023)

New major risk - Financial position

Precipio, Inc., Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: US$4.51 loss per share (vs US$10.73 loss in FY 2022)

Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)

Precipio, Inc. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Precipio, Inc.'s (NASDAQ:PRPO) Subdued P/S Might Signal An Opportunity

Consensus revenue estimates increase by 11%

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Market cap size

New minor risk - Share price stability

Precipio, Inc.'s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings released: US$0.54 loss per share (vs US$0.40 loss in FY 2021)

Price target decreased to US$4.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Precipio Receives Noncompliance Letter from the Nasdaq

Precipio, Inc. Appoints Sharon Robins as its Senior Director of Laboratory & Hospital Sales for the Product’s Division

Precipio, Inc. Launches New 1-Step Technology for All Hemescreen Assays

Second quarter 2022 earnings released: US$0.094 loss per share (vs US$0.14 loss in 2Q 2021)

Precipio, Inc. Welcomes Toni-Ann Mills as its Senior Director for Learning & Development

Forecast to breakeven in 2023

Precipio to distribute HemeScreen through Fisher Healthcare channel

Precipio, Inc. Appoints Keith Meadors as Senior Vice President of its Products Division

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Precipio Signs First IV-Cell Customer Agreement

Price target decreased to US$4.00

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Precipio, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.20 loss in 2Q 2020)

Precipio terminates its equity line with Lincoln Park

We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation

Precipio, Inc. Launches Hemescreen® Anemia Panel, One-Of-Its-Kind Testing Tool

Precipio shares surge on HemeScreen Anemia Panel launch

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.78 loss in 1Q 2020)

Precipio, Inc. Launches New Hemescreen Panel for AML, with an Unparalleled 4-Hour Turnaround-Time

Precipio shares surge on launching hemescreen panel for Acute Myeloid Leukemia

Precipio: COVID-19 Testing At Amazon Is An Impressive Yet Transitory Fluke

Precipio, Inc. Launches Rapid COVID-19 Antibody Test on Amazon Platform

Precipio shares jump on launching its rapid COVID-19 antibody test on Amazon platform

Price target increased to US$7.00

Precipio, Inc. to Report Q4, 2020 Results on Mar 31, 2021

Precipio, Inc. Announces Board and Committee Changes

Precipio Launches COVID-19 Antibody Testing at Point-of-Care

Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups

Precipio, Inc. Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor

Precipio & ADS Biotec Launch Seven Beta Sites for IV-Cell™

Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel

Precipio, Inc.(NasdaqCM:PRPO) dropped from Russell Microcap Value Index

Precipio, Inc.(NasdaqCM:PRPO) dropped from Russell Microcap Index

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

マネジメント基準チェック /44